Advancing Clinical Trial Protocol Authoring: ICH M11, Regulatory Shifts & AI

🔔 Landmark Shift: Starting January 31, 2025, all clinical trials in the EU must comply with the EU Clinical Trial Regulation (CTR) (Source: European Medicines Agency).

For medical writers, this shift is more than a regulatory change—it’s an opportunity to rethink how protocols are authored. With the growing emphasis on standardized templates, structured content, and AI-driven tools, our role is evolving in exciting ways. My experience consulting with biotech, pharma, and an AI company has given me valuable insights into how these advancements can shape the future of protocol development. 

AI-powered tools and structured templates are transforming clinical trial protocol authoring, enabling real-time insights, automation, and improved regulatory compliance.

Reflecting on Protocol Authoring

When I began authoring protocols, the focus was on ensuring consistency, clarity, and compliance. While these priorities remain unchanged, the process often felt static—protocols were lengthy, text-heavy, and not inherently adaptable to evolving trial needs.

Incorporating adaptive elements, like flexible sample sizes, cohort expansion, or dynamic stratification criteria, required meticulous pre-planning and often added layers of complexity. For example, justifying interim analyses or outlining conditions for dose adjustments involved extensive documentation and multiple stakeholder reviews. Yet, despite all the planning, 3 to 5 amendments per trial were common, nearly half of which could have been avoided (Getz et al., 2016). Each amendment triggered ripple effects, such as re-approvals, document revisions, retraining, and delays of weeks or months.

Structured templates were already a part of the workflow when I started. They introduced much-needed consistency, offering predefined sections for key protocol components like study objectives and eligibility criteria. For example, reusing a standardized Schedule of Assessments saved time when creating related documents, like Clinical Study Reports or another protocol. However, updates remained manual and resource-intensive, leaving protocols static and unable to adapt efficiently to new insights or trial needs. 

Landscape Shift with AI

The landscape is shifting again, with tools aligned with ICH M11 and the integration of AI transforming protocol authoring. These advancements are making protocols more dynamic, adaptive, and impactful by enabling real-time insights, modular updates, and data-driven decisions.

These tools are positioned to enhance structured templates and enable medical writers to approach protocol authoring more strategically. For me, these advancements represent more than just technical innovation—they signal a shift in how medical writers contribute to clinical trials. The focus is no longer solely on compliance, clarity, and consistency but on creating protocols that actively support better trial outcomes while making the process more rewarding.

While AI enhances structured templates and streamlines protocol development, challenges remain, including risks of over-standardization, lack of contextual understanding, data privacy concerns, and the need for human oversight to ensure quality and adaptability.

Looking Ahead

As medical writers, we have the unique opportunity to bridge the gap between cutting-edge tools and the foundational principles of clarity, compliance, consistency, and collaboration. Looking ahead, I am eager to explore how AI and structured content can continue to empower the protocol authoring process.

----------------------------------------------------------------------------------------------------------------------------------

Getz KA, Stergiopoulos S, Short M, et al. The Impact of Protocol Amendments on Clinical Trial Performance and Cost. Ther Innov Regul Sci. 2016;50(4):436-441. doi: 10.1177/2168479016632271